{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Stephen+Doughty&answeringDeptId=201&max-ddpModified.=2021-06-10T15%3A00%3A12.939Z&min-answer.questionFirstAnswered.=2021-01-27T17%3A18%3A03.563Z&answer.answeringMemberConstituency=Stratford-on-Avon&registeredInterest=false", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography+information+for+Stephen+Doughty&answeringDeptId=201&max-ddpModified.=2021-06-10T15%3A00%3A12.939Z&min-answer.questionFirstAnswered.=2021-01-27T17%3A18%3A03.563Z&answer.answeringMemberConstituency=Stratford-on-Avon&registeredInterest=false", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Stephen+Doughty&answeringDeptId=201&max-ddpModified.=2021-06-10T15%3A00%3A12.939Z&min-answer.questionFirstAnswered.=2021-01-27T17%3A18%3A03.563Z&answer.answeringMemberConstituency=Stratford-on-Avon&registeredInterest=false&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Stephen+Doughty&_page=0&answeringDeptId=201&max-ddpModified.=2021-06-10T15%3A00%3A12.939Z&min-answer.questionFirstAnswered.=2021-01-27T17%3A18%3A03.563Z&answer.answeringMemberConstituency=Stratford-on-Avon&registeredInterest=false", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Stephen+Doughty&answeringDeptId=201&max-ddpModified.=2021-06-10T15%3A00%3A12.939Z&min-answer.questionFirstAnswered.=2021-01-27T17%3A18%3A03.563Z&answer.answeringMemberConstituency=Stratford-on-Avon&registeredInterest=false", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Stephen+Doughty&answeringDeptId=201&max-ddpModified.=2021-06-10T15%3A00%3A12.939Z&min-answer.questionFirstAnswered.=2021-01-27T17%3A18%3A03.563Z&answer.answeringMemberConstituency=Stratford-on-Avon&registeredInterest=false", "items" : [{"_about" : "http://data.parliament.uk/resources/1330137", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1330137/answer", "answerText" : {"_value" : "<p>The Department for Business, Energy and Industrial Strategy (BEIS) collates and publishes annually information on how much steel is purchased for the Government\u2019s major infrastructure projects in the previous financial year, including what proportion is produced in the UK. This year\u2019s data was published on 19 May and can be found at: <a href=\"http://www.gov.uk/government/publications/steel-public-procurement-2021\" target=\"_blank\">www.gov.uk/government/publications/steel-public-procurement-2021<\/a>.<\/p><p> <\/p><p>The reported value of UK steel procured in 2019/20 for major public projects was £108m, a 33% increase on the previous year. BEIS will start collating data for 2020/21 in due course.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-06-10T14:28:51.607Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-06-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Infrastructure: Iron and Steel"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, how much UK-produced steel reinforcing bar was procured for Government-funded infrastructure projects in each of the last three years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4264", "label" : {"_value" : "Biography information for Stephen Doughty"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff South and Penarth"}
      , "tablingMemberPrinted" : [{"_value" : "Stephen Doughty"}
      ], "uin" : "11567"}
    , {"_about" : "http://data.parliament.uk/resources/1281032", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1281032/answer", "answerText" : {"_value" : "<p>When fully operationally in 2022, the Vaccines Manufacturing and Innovation Centre (VMIC) will have several Good Manufacturing Process suites that will be able to accommodate a range of production scale capabilities. For pandemic response, the VMIC will be able to make up to 70 million doses of a vaccine within a 6-month timeframe. This is a significant increase to the VMIC\u2019s originally anticipated capacity.<\/p><p> <\/p><p>The VMIC has been designed to be a flexible manufacturing facility and will be able to manufacture a range of vaccine types, such as messenger RNA, viral vector, or protein sub-unit.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-02-01", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-01T16:13:48.117Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-01-27", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Vaccine Manufacturing and Innovation Centre: Finance"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 26 January 2021 to Question 141474, how many additional vaccine doses per month the expanded Vaccine Manufacturing Innovation Centre facility can produce as a result of the investment outlined in that Answer; and of which types of vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4264", "label" : {"_value" : "Biography information for Stephen Doughty"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff South and Penarth"}
      , "tablingMemberPrinted" : [{"_value" : "Stephen Doughty"}
      ], "uin" : "144691"}
    , {"_about" : "http://data.parliament.uk/resources/1280122", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1280122/answer", "answerText" : {"_value" : "<p>The Vaccines Manufacturing and Innovation Centre (VMIC) should be partially open in summer 2021, with the facility fully operational in 2022. The VMIC is working towards having fill-finish capability at the end of 2021. The objective remains to accelerate the readiness of the VMIC by a year and it is on track to achieve this, but it is also important to remember this is a complex project being delivered in unprecedented times.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-01-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-01-28T17:21:34.833Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-01-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Vaccine Manufacturing and Innovation Centre"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, when the expansion of the VMIC facility is planned to be completed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4264", "label" : {"_value" : "Biography information for Stephen Doughty"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff South and Penarth"}
      , "tablingMemberPrinted" : [{"_value" : "Stephen Doughty"}
      ], "uin" : "142941"}
    , {"_about" : "http://data.parliament.uk/resources/1280124", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1280124/answer", "answerText" : {"_value" : "<p>The Government is currently undertaking its own laboratory work as a priority to better understand the impact of the new Covid-19 variants on the vaccines currently in deployment, in particular the risk of vaccine resistance. We maintain close contact with vaccine developers to understand their own studies as to the efficacy of their vaccines on variants and the impact on current supply chain arrangements for their manufacture.<\/p><p> <\/p><p>We continue to take a portfolio-based approach that monitors the landscape of Covid-19 vaccine development and we remain confident that the three vaccines (Pfizer/BioNTech, Oxford University/AstraZeneca, and Moderna) that we have purchased, which have been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), will continue to be effective against the virus.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-01-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-01-28T17:19:44.303Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-01-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, whether the (a) design, (b) bio-engineering and (c) manufacture of vaccines capable of responding to the 501 and 484 variants of covid-19 has commenced.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4264", "label" : {"_value" : "Biography information for Stephen Doughty"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff South and Penarth"}
      , "tablingMemberPrinted" : [{"_value" : "Stephen Doughty"}
      ], "uin" : "142942"}
    , {"_about" : "http://data.parliament.uk/resources/1280125", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1280125/answer", "answerText" : {"_value" : "<p>The Government is currently undertaking its own laboratory work as a priority to better understand the impact of the new Covid-19 variants on the vaccines currently in deployment, in particular the risk of vaccine resistance. We maintain close contact with vaccine developers to understand their own studies as to the efficacy of their vaccines on variants and the impact on current supply chain arrangements for their manufacture.<\/p><p> <\/p><p>We continue to take a portfolio-based approach that monitors the landscape of Covid-19 vaccine development and we remain confident that the three vaccines (Pfizer/BioNTech, Oxford University/AstraZeneca, and Moderna) that we have purchased, which have been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), will continue to be effective against the virus.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-01-28", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-01-28T17:17:49.753Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-01-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, when vaccines capable of responding to the 501 and 484 variants of covid-19 will be available for use in the general population.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4264", "label" : {"_value" : "Biography information for Stephen Doughty"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff South and Penarth"}
      , "tablingMemberPrinted" : [{"_value" : "Stephen Doughty"}
      ], "uin" : "142943"}
    , {"_about" : "http://data.parliament.uk/resources/1279579", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1279579/answer", "answerText" : {"_value" : "<p>The Government has procured 40 million doses of the Pfizer/BioNTech and 100 million doses of the Oxford University/AstraZeneca vaccines.<\/p><p> <\/p><p>The UK was the first country in the world to start a vaccination programme using these vaccines. As of 26 January 2021, over 6.85 million people across the UK have been vaccinated with the first dose of the vaccine. We continue to work to meet our target of vaccinating all four priority groups by 15 February.<\/p><p> <\/p><p>Vaccines are a precious resource in very high demand across the world; therefore, for security reasons it is not possible to provide detail about the size of our supplies and exact detail about deliveries.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-01-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-01-27T17:19:30.99Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-01-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, how many doses of the (a) Pfizer-BioNTech and (b) Oxford-AstraZeneca vaccine are physically present in the UK and being held in storage, yet to be deployed or prepared for delivery.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4264", "label" : {"_value" : "Biography information for Stephen Doughty"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff South and Penarth"}
      , "tablingMemberPrinted" : [{"_value" : "Stephen Doughty"}
      ], "uin" : "141990"}
    , {"_about" : "http://data.parliament.uk/resources/1279593", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1279593/answer", "answerText" : {"_value" : "<p>The Government has made several strategic investments in UK vaccine manufacturing capabilities to increase its capacity, ensuring we are able to manufacture across different vaccine technologies and embed resilience. This includes:<\/p><p> <\/p><ul><li>The acceleration and expansion of flexible vaccine manufacturing capabilities at the UK\u2019s first Vaccine Manufacturing and Innovation Centre (VMIC) in Harwell.<\/li><li>Collaborating with the Cell and Gene Therapy Catapult to fund a state-of-the-art Manufacturing Innovation Centre in Braintree.<\/li><li>Expansion of the Valneva factory in Livingston, Scotland, which is capable of whole virus manufacture.<\/li><\/ul><p> <\/p><p>Both the VMIC and Braintree sites are flexible to vaccine types, including messenger RNA (mRNA), viral vector, and protein sub-unit. These sites could have a role in providing capability to manufacture vaccines to address the emerging variants of the COVID-19 virus.<\/p><p> <\/p><p>The Government has also invested through UK Research and Innovation (UKRI) to support the creation of a new Centre of Excellence in mRNA vaccine manufacture at the Centre for Process Innovation (CPI), with equipment that can manufacture mRNA for vaccines. This funding has upgraded CPI\u2019s National Biologics Manufacturing Centre at Darlington to obtain good manufacturing practice certification for the manufacture of RNA products including mRNA for clinical trials. A key advantage of RNA vaccines is how quickly they can be developed compared with other platforms.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
        }
        , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
        , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
        , "dateOfAnswer" : {"_value" : "2021-01-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-01-27T17:18:03.563Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2021-01-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, how many UK based manufacturing facilities are capable of re-engineering and manufacturing (a) mRNA, (b) viral vector, (c) whole virus and (d) protein subunit vaccines to address emerging variants of the covid-19 virus.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4264", "label" : {"_value" : "Biography information for Stephen Doughty"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff South and Penarth"}
      , "tablingMemberPrinted" : [{"_value" : "Stephen Doughty"}
      ], "uin" : "141992"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 7, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}